Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so updates cover how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE: LLY) announced an additional $4.5 billion investment across two Lebanon, Indiana sites and opened Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility, on May 6, 2026.
The move raises Lilly's Indiana capital commitments since 2020 to $21 billion and its U.S. commitments since 2020 to more than $50 billion. Planned production at the Lebanon campus includes Foundayo and retatrutide, and the Lebanon API site is slated to open in 2027 as the largest U.S. API production site in history.
Lilly (NYSE: LLY) reported that Omvoh (mirikizumab-mrkz) is the first IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years.
In the LUCENT-3 open-label extension, 63.5% of patients who achieved disease clearance at one year sustained it at four years; 61.3% sustained disease clearance with endoscopic normalization. Long-term safety was consistent with known profiles: 12% serious adverse events and 7% discontinued for adverse events.
Eli Lilly and Company (NYSE:LLY) declared a second-quarter 2026 cash dividend of $1.73 per share. The dividend is payable on June 10, 2026 to shareholders of record at the close of business on May 15, 2026.
Eli Lilly (NYSE:LLY) reported Q1 2026 revenue of $19.8 billion, up 56%, and raised full‑year revenue guidance to $82.0–$85.0 billion with non‑GAAP EPS guidance of $35.50–$37.00. Q1 reported EPS was $8.26 and non‑GAAP EPS was $8.55. Key drivers included strong volume for Mounjaro and Zepbound, FDA approval and U.S. availability of oral GLP‑1 Foundayo, multiple Phase 3 wins, and four announced acquisitions.
Eli Lilly (NYSE: LLY) agreed to acquire Ajax Therapeutics to obtain AJ1-11095, a first-in-class, once-daily oral Type II JAK2 inhibitor in a Phase 1 trial for myelofibrosis and polycythemia vera. Dose selection and proof-of-concept data are expected in 2026. Ajax shareholders may receive up to $2.3 billion in cash, including upfront and milestone payments. The deal is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance. Lilly plans rapid advancement toward registrational trials and will reflect the transaction in its GAAP financials after close.
Eli Lilly (NYSE:LLY) agreed to acquire Kelonia Therapeutics to broaden Lilly's genetic medicine and in vivo CAR-T capabilities. The deal offers Kelonia shareholders up to $7.00 billion in cash, including a $3.25 billion upfront payment. KLN-1010, Kelonia's Phase 1 in vivo BCMA CAR-T, showed encouraging data at the 2025 ASH plenary session. The transaction is expected to close in H2 2026 and remains subject to customary regulatory approvals and closing conditions.
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. A conference call with investors, media and the public will begin at 10:00 a.m. Eastern that day and will be webcast live.
According to the company, a replay of the webcast will be posted on the investor website at https://investor.lilly.com/webcasts-and-presentations following the call.
Eli Lilly (NYSE:LLY) reported topline Phase 3 ACHIEVE-4 results for Foundayo (orforglipron) on April 16, 2026. Foundayo met the primary non-inferiority MACE-4 endpoint (HR 0.84; 95% CI 0.59–1.20) and showed superior A1C and weight reductions at 52 weeks vs insulin glargine. A pre-planned analysis reported 57% lower all-cause death (HR 0.43; 95% CI 0.25–0.75). Lilly plans an FDA submission for type 2 diabetes by end of Q2 2026.
Lilly (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-322 trial showing that adding Jaypirca (pirtobrutinib) to venetoclax plus rituximab produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in relapsed/refractory CLL/SLL.
Results were consistent across subgroups, including patients previously treated with covalent BTK inhibitors. Overall survival was immature but trended favorably. Safety was consistent with known profiles and discontinuation rates were low and similar between arms. Lilly plans regulatory submissions later in 2026.
Eli Lilly (NYSE: LLY) announced Foundayo (orforglipron) is now available in the U.S. after FDA approval on April 1, 2026, with retail pharmacy shipping beginning April 9, 2026.
Foundayo is a once-daily oral GLP-1 for adults with obesity or overweight with weight-related problems, showing an average weight loss of 27.3 pounds (12.4%) at the highest dose in ATTAIN-1.